Six analysts have recently reviewed Catalent (NYSE:CTLT), all maintaining an indifferent stance with no changes in bullish or bearish ratings over the past three months. The average 12-month price target for CTLT has been raised to $60.75, indicating a 13.19% increase from the previous target. Despite this optimistic target adjustment, Catalent faces financial challenges, including lower market capitalization, revenue decline of -10.88%, and below-average profitability metrics such as net margin, ROE, and ROA. The company's debt-to-equity ratio also exceeds industry norms, suggesting potential financial risks.